United Therapeutics
UTHR
508 hedge funds and large institutions have $10.1B invested in United Therapeutics in 2023 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 172 increasing their positions, 181 reducing their positions, and 33 closing their positions.
121% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 33
29% more funds holding in top 10
Funds holding in top 10: 14 → 18 (+4)
7% more funds holding
Funds holding: 473 → 508 (+35)
1% more capital invested
Capital invested by funds: $9.94B → $10.1B (+$119M)
5% less repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 181
1.38% less ownership
Funds ownership: 96.16% → 94.78% (-1.4%)
29% less call options, than puts
Call options by funds: $25.6M | Put options by funds: $36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$26.8M |
| 2 |
NC
Nitorum Capital
New York
|
+$25.7M |
| 3 |
Amundi
Paris,
France
|
+$20.3M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$15.9M |
| 5 |
Renaissance Technologies
New York
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$131M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$91.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$42.7M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$34.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$24.5M |
UTHR Hedge Fund Activity: Q3 2023 in Review
508 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2023, worth a combined $10.1B — up 1.2% from $9.94B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new UTHR positions and 33 closed out — a net gain of 40 holders — while 172 added to existing stakes and 181 trimmed.
The largest buyer was Millennium Management, adding an estimated $26.8M. The largest seller was Wellington Management Group, cutting an estimated $131M.
- 508 institutional investors held United Therapeutics (UTHR) as of Q3 2023, up from 473 in Q2 2023.
- Funds reported $10.1B of United Therapeutics stock for Q3 2023, up 1.2% quarter-over-quarter.
- 73 funds opened new United Therapeutics positions in Q3 2023 and 33 closed out, a net change of +40 holders.
- The largest United Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $26.8M added.
- The largest United Therapeutics seller in Q3 2023 was Wellington Management Group, an estimated $131M sold.
Based on aggregated 13F filings for Q3 2023.